ACP issues guidance statement for breast cancer screening of average-risk women with no symptoms

The age to start and discontinue mammography, screening intervals, the role of imaging methods other than mammography, and the role of clinical breast examination have been points of disagreement among guideline developers.


Average-risk women between the ages of 50 and 74 years who have no symptoms for breast cancer should undergo breast cancer screening with mammography every other year, ACP stated in a new evidence-based guidance statement published earlier this week in Annals of Internal Medicine.

ACP's guidance statement does not apply to patients with prior abnormal screening results or to higher-risk populations, such as women with a personal history of breast cancer or a genetic mutation known to increase risk.

“Beginning at age 40, average-risk women without symptoms should discuss with their physician the benefits, harms, and their personal preferences of breast cancer screening with mammography before the age of 50,” said ACP President Ana María López, MD, MPH, MACP, who is also a medical oncologist. “The evidence shows that the best balance of benefits and harms for these women, which represents the great majority of women, is to undergo breast cancer screening with mammography every other year between the ages of 50 and 74.”

Screening with mammography every other year results in no significant difference in breast cancer mortality while substantially reducing screening harms when compared to annual screening. Women screened annually receive more abnormal results that do not represent an actual breast cancer diagnosis than women screened every other year (7.0% vs. 4.8%). These false-positive findings result in biopsies and surgeries that would otherwise not have been necessary.

About 20% of women diagnosed with breast cancer over a 10-year period will be overdiagnosed and likely overtreated. Therefore, finding this cancer is not of clinical benefit to the woman. Harms of breast cancer screening include false-positive results, overdiagnosis, overtreatment, radiation exposure, and radiation-associated breast cancers and breast cancer deaths, as well as worry and distress from tests and procedures. including breast biopsies.

In an accompanying editorial, Joann G. Elmore, MD, MPH, FACP, and Christoph I. Lee, MD, MS, wrote: “The results of [ACP's] assessment are 4 guidance statements that provide clarity and simplicity amidst the chaos of diverging guidelines. These ACP guidance statements represent convergence across differing recommendations while highlighting important points for physicians to consider in shared decision-making conversations with their patients about routine breast cancer screening.”

Recommended strategies vary for breast cancer screening in average-risk women. The age to start and discontinue mammography, screening intervals, the role of imaging methods other than mammography, and the role of clinical breast examination have been points of disagreement among guideline developers. Rather than developing a new clinical practice guideline in these circumstances, ACP instead prepares and releases guidance statements that rely on evidence presented or referenced in selected guidelines and accompanying evidence reports. ACP guidance statements do not include new reviews or searches of the literature outside the body of evidence referenced by the reviewed guidelines.

In “Screening for Breast Cancer in Average-risk Women,” ACP reviewed guidelines from the American College of Radiology, American Cancer Society, American College of Obstetricians and Gynecologists, the Canadian Task Force on Preventive Health Care, the National Comprehensive Cancer Network, the U.S. Preventive Services Task Force, and the World Health Organization.